Last reviewed · How we verify

Medical treatment

University of Sao Paulo General Hospital · FDA-approved active Small molecule Quality 5/100

Medical treatment is a Small molecule drug developed by University of Sao Paulo General Hospital. It is currently FDA-approved. Also known as: Timoptol 0,5%, Xalatan, Trusopt, Alphagan.

At a glance

Generic nameMedical treatment
Also known asTimoptol 0,5%, Xalatan, Trusopt, Alphagan, Duloxetine
SponsorUniversity of Sao Paulo General Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Medical treatment

What is Medical treatment?

Medical treatment is a Small molecule drug developed by University of Sao Paulo General Hospital.

Who makes Medical treatment?

Medical treatment is developed and marketed by University of Sao Paulo General Hospital (see full University of Sao Paulo General Hospital pipeline at /company/university-of-sao-paulo-general-hospital).

Is Medical treatment also known as anything else?

Medical treatment is also known as Timoptol 0,5%, Xalatan, Trusopt, Alphagan, Duloxetine.

What development phase is Medical treatment in?

Medical treatment is FDA-approved (marketed).

Related